期刊
INTERNATIONAL JOURNAL OF PHARMACEUTICS
卷 635, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ijpharm.2023.122711
关键词
Docetaxel; Albumin; Nanoparticles; Anti-cancer drugs; Targeted drug delivery; Preclinical evaluation
A novel albumin-bound docetaxel nanoparticle formulation was developed to improve the solubility and anticancer efficacy of docetaxel. The nanoparticles exhibited similar pharmacokinetic profiles, safety profiles, and superior anticancer efficacy compared to Docetaxel Injection. This study demonstrated the potential of albumin-bound docetaxel nanoparticles for reducing toxicity and enhancing efficacy in clinical applications.
Docetaxel is a highly potent anti-tumor agent which is clinically effective for the treatment of various cancers. However, the clinical application of docetaxel is limited due to its poor solubility. The solvent and cosolvent existing in the complex solvent systems can lead to serious adverse effects in clinical application. This paper aimed to develop a novel formulation of docetaxel with improved aqueous solubility and enhanced anti-tumor efficacy. Novel albumin-bound docetaxel nanoparticles were successfully developed based on the nanoparticle albumin-bound (nabTM) technology platform, showing a perfect particle size of 115.6 nm and high encapsulation efficiency (95.43%). Then the in vivo anti-tumor efficacy, plasma pharmacokinetics, tissue distribution and toxicity profiles of albumin-bound docetaxel nanoparticles were evaluated in comparison with those of Docetaxel Injection. The preclinical study demonstrated that albumin-bound docetaxel nanoparticles exhibited equivalent pharmacokinetic profiles, similar safety profiles and better anti-tumor efficacy on NCI-N87 human gastric car-cinoma and BxPC-3 human pancreatic carcinoma compared with those of Docetaxel Injection. These results indicated that such albumin-bound docetaxel nanoparticles are promising in reducing toxicity and enhancing efficacy in clinical applications, showing great potential for developing an advanced drug delivery system for cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据